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Abstract: A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione
(GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism
for increased GSH levels is to counteract damaging ROS to sustain the viability and growth of the
malignancy. Here, we review the current knowledge about the three main RCC subtypes, namely
clear cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC (chRCC), at the genetic,
transcript, protein, and metabolite level and highlight their mutual influence on GSH metabolism.
A further discussion addresses the question of how the manipulation of GSH levels can be exploited
as a potential treatment strategy for RCC.
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1. Introduction
Increased reactive oxygen species (ROS) levels, including the superoxide anion, hydrogen peroxide,
and hydroxyl radical, have been reported in many different cancer types. ROS can be either generated
by genetic alterations and endogenous oxygen metabolism or by exogenous sources, such as UV light
and radiation. ROS were long thought to be only damaging byproducts of the cellular metabolism that
can negatively affect DNA, lipids, and proteins [1]. However, more recent studies have highlighted the
important role of ROS in cell signaling, homeostasis, metabolism, and apoptosis [1]. One common
characteristic of cancer is the ability to balance the increased level of oxidative stress with a high level of
antioxidants. Glutathione (GSH), a tripeptide thiol antioxidant composed of the amino acids glutamic
acid, cysteine, and glycine [2], is the main ROS scavenger in cells. GSH is highly reactive and exists in
both a reduced (GSH) and oxidized disulfide (GSSG) form [3]. The predominant form is in the reduced
state, which is the most abundant low molecular weight thiol in the cell, ranging from 0.5 to 10 mM in
most cell types, whereas extracellular GSH exists in concentrations lower by magnitudes [4]. The de
novo biosynthesis of GSH involves two ATP-dependent enzymatic reactions: The first step is catalyzed
by glutamate cysteine ligase (GCL), which ligates the amino group of cysteine to the γ-carboxylate of
glutamic acid to form the dipeptide γ-glutamyl cysteine. The second reaction involves GSH synthetase
(GSS), which catalyzes a combination of the cysteinyl carboxylate of the dipeptide and the amino group
of glycine to synthesize GSH [5] (outlined in Figure 1).
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Figure 1. Schematic overview of glutathione (GSH) metabolism and the targeting sites of inhibitors. Color codes 
are defined as follows: black = enzymes or transporters; red = metabolites; blue = inhibitors. GGT: γ-glutamyl 
transferase; xCT: solute carrier family 7 member 11, a cystine-glutamate antiporter; GLS1: glutaminase 1; GCL: 
glutamate cysteine ligase; GSS: glutathione synthetase. GSSG: glutathione oxidized form; ROS: reactive oxygen 
species. 
Besides the classical role of GSH acting as an ROS scavenger by being prey for radicals, GSH has 
several additional functions, including but not limited to providing a cysteine reservoir [6], being 
involved in the maturation of iron–sulfur proteins [7], detoxifying xenobiotics [8], regulating protein 
bioactivity by S-glutathionylation [9,10], and regulating redox signaling [11]. In cancer, GSH plays 
the role of a double-edged sword in its initiation and progression. Moderate ROS levels are widely 
recognized to trigger cancer initiation and progression by inducing mutations and promoting 
genome instability, eventually activating oncogenic signaling pathways that promote cell survival, 
proliferation, and stress resistance [12]. On the contrary, massive ROS accumulations can also limit 
cancer growth by causing severe oxidative damage of biomolecules, which finally can lead to cell 
death [13]. As a consequence, cancer cells are required to deliberately balance the levels of ROS and 
antioxidants (mainly GSH) to maintain redox homeostasis, which sustains viability and growth. For 
many years, one of the most obvious therapeutic strategies to overcome new balanced redox 
homeostasis in renal cell carcinoma (RCC) was to fight elevated ROS levels with the supplementation 
of antioxidants such as vitamins to actively force the tumor into apoptosis. Many clinical trials were 
initiated, and the outcomes showed mixed results, including worse survival rates upon 
supplementation with ROS inhibitors [14]. 
In this review, we will focus on the role of the ROS scavenger GSH in RCC and discuss possible 
strategies that can potentially exploit the manipulation of GSH levels for therapeutic strategies in RCC. 
2. Renal Cell Carcinoma: An Overview 
RCC represents approximately 4% of adult malignancies [15] and was ranked as the sixth 
deadliest cancer worldwide in 2018 [16]. The American Cancer Society estimated that about 73,820 
new RCC cases would be diagnosed by the end of 2019 and more than 14,770 deaths would be caused 
by RCC this year in the USA alone [15]. RCC can be classified according to distinct morphologic and 
molecular genetic features and is composed of different subtypes, such as clear cell RCC (ccRCC), 
Figure 1. Schematic overview of glutathione (GSH) metabolism and the targeting sites of inhibitors.
Color codes are defined as follows: black = enzymes or transporters; red = metabolites; blue = inhibitors.
GGT: γ-glutamyl transferase; xCT: solute carrier family 7 member 11, a cystine-glutamate antiporter;
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2. Renal Cell Carcinoma: An Overview
RCC represents approximately 4% of adult malignancies [15] and was ranked as the sixth deadliest
cancer worldwide in 2018 [16]. The American Cancer Society estimated that about 73,820 new RCC
cases would be diagnosed by the end of 2019 and more than 14,770 deaths would be caused by RCC
this year in the USA alone [15]. RCC can be classified according to distinct morphologic and molecular
genetic features and is composed of different subtypes, such as clear cell RCC (ccRCC), papillary RCC
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(pRCC), and chromophobe RCC (chRCC, Table 1). Many studies have been performed recently to
characterize RCC to better understand its classification and subclassification and to elucidate pathway
remodeling in these cancers [17–19]. A new classification concept based on molecular clustering of
chromosoms, DNA, RNA, miRNA, and protein data was proposed [18,20], where the organ of origin
does not fully determine the tumor type as the only factor [21]. Instead, the cancer classification should
be based on the similarity of molecular features across different tissue types, which was considered to
be more relevant for targeting the same mutations and oncogenic signaling pathways [21].
Here, we review the genetic foundation of the main RCC types and shed light on the sparse data
of transcriptome, proteome, and metabolome profiles performed in these malignancies.
Table 1. Summary of the three renal cell carcinoma (RCC) subtypes, incidences, main mutations, and
GSH regulation.
RCC Subtypes Clear Cell Papillary Chromophobe
Incidence 75% 15% 5%
Main mutations VHL MET, FH TP53, PTEN
Metabolites GSH, GSSG increased GSH, GSSG increased GSH, GSSG increased
GSH regulation
1. GCL protein abundance
increases;
2. Increased serum GGT as a
marker for metastatic ccRCC;
3. GLS1, glutamine importers,
and cysteine antiporter xCT
enhance to favor GSH synthesis;
4. Increased PPP flux to produce
NADPH for GSH conversion.
1. FH mutation causes HIF
stabilization;
2. FH mutation activates
NRF2–ARE pathway, leading
to increased GSH synthesis
and enhanced expression of
antioxidant proteins.
Loss of GGT1 increases
sensitivity to oxidative
stress in chRCC cells.
ccRCC: clear cell RCC; chRCC: chromophobe RCC; pRCC: papillary RCC; VHL: von Hippel-Lindau; MET:
proto-oncogene c-Met; FH: fumarate hydrotase; TP53: tumor antigen p53; PTEN: phosphatase and tensin homolog;
PPP: pentose phosphate pathway; HIF: hypoxia-inducible factor; NRF2: nuclear factor erythroid 2-related factor 2;
ARE: antioxidant response element; GGT1: γ-glutamyl transferase 1.
2.1. Clear Cell Renal Cell Carcinoma
Clear cell RCC is the most prevalent subtype and accounts for about 75% of all RCCs (Table 1) [22].
It is an aggressive cancer that originates from the proximal convoluted tubule, with a recurrence
rate of up to 40% after the initial treatment of a localized tumor [23]. In its metastatic form, it is
associated with a high mortality rate [24]. Clear cell RCC cells have, in general, a clear cytoplasm,
(which helped coin the name “clear cell”) that is circled by an easily distinguishable cell membrane and
uniform round nuclei [25]. About 90% of all ccRCCs carry mutations in the von Hippel-Lindau (VHL)
tumor suppressor gene [17,26], which was originally identified in a hereditary disease called VHL
syndrome [27]. The VHL protein is a target recruitment subunit in an E3 ubiquitin ligase complex and
recruits the hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions for subsequent
proteasomal degradation. Thereby, VHL can repress the transcription of more than 100 target genes
through interaction with HIF1α and HIF1AN, which plays a vital role in forming the phenotype of
ccRCC [28]. HIF1α is a master transcription factor that contributes substantially to the regulation of
gene expression that is dependent on oxygen levels. Under normoxic conditions, VHL interacts with
HIF1α and hydroxylates the proline residues in the oxygen-dependent degradation (ODD) domains of
HIF1α by recruiting members of the Egl-nine homolog (EGLN) family [28–30]. With hypoxia or loss
of function of VHL, these proline residues cannot be hydroxylated, which stabilizes HIF1α. HIF1α
subsequently forms a HIF1α–HIF1β heterodimer, and this dimer translocates into the nucleus to
enhance the transcription of HIF target genes, which are associated with crucial oncogenic pathways,
including glucose uptake, glycolysis (e.g., glucose transporter type 1, GLUT1), cell proliferation
(e.g., epidermal growth factor receptor, EGFR), and angiogenesis (vascular endothelial growth factor,
VEGF) [30–33].
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Furthermore, the gluconeogenic enzyme fructose 1,6-bisphosphatase 1 (FBP1) has been found to
be decreased in over 600 ccRCCs and has been associated with poor disease prognosis. FBP1 has two
distinct functions, antagonizing the glycolytic flux and inhibiting the nuclear function of HIFα [34],
which can explain its ubiquitous loss in ccRCC [34]. Besides FBP1, the whole gluconeogenesis pathway
has been shown to be severely diminished in ccRCC at the transcriptome [34] and proteome level [35].
This stimulates the metabolic switch by increasing glycolytic target genes [34], which is reflected by
the metabolomic analysis of ccRCC, where metabolites in the glycolysis pathway show over two-fold
increases in abundance compared to the normal kidney [36]. Furthermore, GSH metabolism-related
metabolites, including cysteine, γ-glutamyl cysteine, and GSH, have all been shown to increase in
late-stage ccRCC and are associated with worse survival outcomes in ccRCC patients [36].
2.2. Papillary Renal Cell Carcinoma
Papillary RCC represents about 15% of all RCCs (Table 1) and also derives from the proximal
convoluted tubule, similarly to ccRCC [22]. It is a less aggressive subtype compared to ccRCC and
has a high five-year survival rate of 80% to 85% [37]. The term “papillary” describes the papilla-like
protuberances in most of the tumors. It can be further subdivided into type I and type II tumors based
on morphological features. Type I pRCC is more common and shows small fibrovascular papillae
that are covered by a single layer of small cuboidal cells with scant pale cytoplasm and usually grows
slowly [38]. In contrast, type II pRCC consists of papillae, is lined by large columnar pseudostratified
cells with an eosinophilic cytoplasm, and is often more aggressive [38,39]. Type I and type II pRCC
have also been shown to be clinically and biologically distinct, as alterations in the MET pathway
were associated with type I [18,40]. The proto-oncogene c-Met (MET) protein, a transmembrane
receptor tyrosine kinase, can bind to its ligand hepatocyte growth factor (HGF) and activate several
downstream intracellular pathways, including focal adhesion kinase (FAK), RAS/RAF/MEK/ERK,
and PI3K/AKT [41]. The frequently activating mutations and amplification of MET in type I pRCC
enable the activation of MET/HGF signaling and its above-mentioned downstream pathways to
promote cancer cell proliferation, angiogenesis, and malignant transformation [41].
Frequent mutations in type II pRCC includeCDKN2A silencing, SETD2mutations, and TFE3 fusions.
Type II tumors are characterized by increased expression of the nuclear factor erythroid 2-related factor 2
(NRF2)–antioxidant response element (ARE) pathway [18]. The NRF2–ARE pathway is a major regulator
of cellular redox balance, and its activation under oxidative stress favors cell survival. Furthermore,
fumarate hydratase (FH) mutations are also frequently found in type II pRCC [42,43]. The FH gene
encodes a TCA cycle enzyme that catalyzes the hydration of fumarate to malate, and its deficiency causes
fumarate and succinate accumulation [44,45]. Accumulated fumarate and succinate are believed to be
able to suppress the hydroxylation of the proline residues in the ODD domain of HIFα, and thus FH
mutations in type II pRCC also cause the stabilization of HIFα, similarly to ccRCC [44,45]. Some genes
(such as CDKN2A/B and TERT) where mutations can be found in both types [40] play a pivotal role as
tumor suppressors by regulating the cell cycle. Mutations of the above-mentioned genes and activation
of the oncopathways are the main driver mutations in the progression of pRCC.
How do these genetic alterations in pRCC translate to the protein and metabolite level? Proteome
profiles of pRCC versus matching healthy tissues have indicated a tremendous reprogramming of main
metabolic pathways. Oxidative phosphorylation, the TCA cycle, branched-chain amino acids, cytochrome
P450 drug metabolism, peroxisomes, fatty acid metabolism, and several amino acid metabolism pathways
were significantly decreased in pRCC, whereas the spliceosome, the ribosome, and the cell cycle were
significantly increased [46]. A striking anticorrelation between the proteome and the transcriptome
data [18] was identified for oxidative phosphorylation. Transcripts of the respiratory chain were
significantly increased in pRCC, whereas the entire pathway was significantly decreased on the proteome
level. Most likely, the lower protein abundance of the respiratory chain was a consequence of the reduced
mitochondrial DNA (mtDNA) content in pRCC, as a similar association was observed in ρ0 cells [47].
ρ0 cells entirely lacking mtDNA, which encodes for 13 core respiratory chain subunits and consequently
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miss all of the respiratory chain complexes [47]. Furthermore, the discrepancy between the transcripts
and proteins of the respiratory chain in RCC can also originate from the regulation of post-translational
modifications. The metabolome indicated a tremendous increase of reduced and oxidized GSH levels in
pRCC tissues [46], as well as significantly increased rates of GSH de novo synthesis based on glutamine
consumption in the pRCC-derived cell lines Caki-2 and ACHN [46]. All of these alterations can in
principle serve as potential therapeutic targets. Specifically, a dysregulated respiratory chain can cause
electron leakage [48,49]. This, in turn, leads frequently to an increase in ROS stress [50,51], which is
subsequently compensated for by increased GSH levels in RCC and might serve as a main therapeutic
site to eradicate RCC, as discussed later on.
2.3. Chromophobe Renal Cell Carcinoma
Chromophobe RCC accounts for approximately 5% of all RCCs (Table 1) [22], is thought to
originate from the cortical collecting duct, and was first reported in 1985 [52]. Different morphological
and ultrastructural features of the cytoplasm lead to the identification of the classical chromophobe
and the eosinophilic variant. The cells of the classical type usually have abundant clear cytoplasm and
a perinuclear halo caused by cytoplasmic organelles being pushed away from the center to form a rim
along the cell membrane [53]. The eosinophilic type has, in general, smaller cells with an inconstant
level of cytoplasmic organelles in the periphery. Both cell types frequently coexist in chRCC tumors,
usually with one cell type predominating [53]. One of the most characteristic genetic features of chRCC
is the monosomy of chromosomes 1, 2, 6, 10, 13, 17, and often 21 [54–57]. The most commonly mutated
genes in chRCC are TP53 (32%), PTEN (20%), and gene fusions involving the TERT promoter [19,54].
Mutations in these tumor suppressors combined with the deletion of one of their chromosomes leads to
a complete loss of function. Further mutations with a lower frequency were observed in MTOR, NRAS,
TSC1, and TSC2, indicating that the genomic targeting of the mTOR pathway occurred in 23% of all
chRCC [19]. Hence, the anticancer functions of TP53 in apoptosis, genomic stability, and the inhibition
of angiogenesis and the role of PTEN in the intracellular signaling pathway PI3K/AKT/mTOR are both
disrupted and can thus be regarded as major driving events in chRCC tumorigenesis.
Proteome profiling has identified metabolic reprogramming in chRCC, including stalled
gluconeogenesis, downregulated oxidative phosphorylation, and fatty acid and amino acid metabolism [57].
A similar anticorrelation between transcripts and proteins (as in pRCC) was also identified in chRCC.
As chRCC has a significantly lower microvessel density and a lower glucose uptake rate compared
to ccRCC and pRCC [58,59], it seems that chRCC cells prefer a different way to acquire nutrients to
compensate for the nutrient-poor microenvironment. Chromophobe RCC cells can activate the endocytosis
and downstream lysosomal pathways to gain extracellular macromolecules as a nutrition source for cell
survival and proliferation, which is indicated by the abundance increase of proteins involved in these
pathways and their enzymatic activities [57]. Metabolome profiling in chRCC [57,60] and the closely
related but hardly distinguishable benign renal oncocytomas [61,62] has also elucidated a striking increase
of GSH and GSSG levels in kidney tumors, thus a hallmark in all RCCs.
In the next chapters, we will investigate the role of GSH metabolism in RCC progression and how
this adaption to increased ROS levels can be exploited therapeutically.
3. Rewired Glutathione Metabolism in RCC Is a Key Metabolic Alteration Involved in Tumor
Progression
3.1. γ-Glutamyl Cycle and ccRCC Progression
The γ-glutamyl cycle was originally proposed by Meister in 1970 and involves the de novo
biosynthesis and degradation of GSH [63]. Its main functions rely on the two enzymes GCL and GSS
for biosynthesis and γ-glutamyl transferases (GGTs) for degradation (Figure 1).
GCL is involved in the first step of de novo GSH synthesis, which catalyzes the reaction of
γ-glutamyl cysteine production. Other than substrate availability, GCL is the rate-limiting enzyme
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of GSH biosynthesis. It is composed of two different subunits: GCLC, the 73-kD catalytic subunit,
which contains the active site for catalyzing the reaction; and GCLM, the 31-kD modulatory subunit,
which interacts with GCLC to increase catalytic efficiency [64]. Under physiological conditions,
the activity of the GCLC/GCLM heterodimer can be regulated by a negative feedback loop by its
product GSH [5]. GCLC and GCLM were reported to have increased protein abundances, matching the
significantly increased enzymatic activity in the tumor tissues of ccRCC patients [34,65,66]. Validation
by siRNA-mediated silencing of GCLC led to a strong cell number reduction of ccRCC cell lines, which
was accompanied by significantly decreased GSH levels [66]. The direct inhibition of GSH synthesis
caused ferroptosis, a nonapoptotic form of cell death, in ccRCC cells [66]. These data support the
substantial role of GSH metabolism in ccRCC progression.
GGTs are membrane-bound, N-terminal nucleophile hydrolases that catalyze the breakdown of
extracellular GSH and transfer the γ-glutamyl group from GSH to produce the constituents glutamate
and cysteine, which can be further used for intracellular GSH synthesis (Figure 1) [67]. Increased
serum GGT was reported to be a sensitive marker for metastatic ccRCC [68], as GGT levels positively
correlated with advanced stages, higher grades, and the presence of tumor necrosis, and it was further
associated with worse survival rates in ccRCC patients [69].
3.2. Precursor Amino Acid Availability for GSH de novo Synthesis
Apart from the γ-glutamyl cycle, GSH de novo synthesis also relies on the availability of its three
composing amino acids—glutamate, cysteine, and glycine—and the activity of their corresponding
transporters, as summarized in Figure 2.
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One of the metabolic hallmarks of ccRCC is the addiction to glutamine. The malignancies, therefore,
require exogenous glutamine for growth and feature reprogrammed glutamine metabolism [70,71].
The availability of glutamine can directly or indirectly influence GSH de novo synthesis in three
different ways. First, glutamine can be converted to glutamate by two isozymes, glutaminase 1 and
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2 (GLS1 and GLS2). GLS1 is increased in many cancer types and is the main isoform within the
kidney [72]. Second, glutamine-related transporter transcripts are consistently increased in ccRCC
tumors, e.g., the glutamine importers SLC38A1 and SLC38A2 [73], to sustain glutaminolysis in ccRCC.
Interestingly, SLC38A1 expression is also regulated by MYC in K562 and HeLa cells: Considering
that MYC has been shown to be upregulated and that MYC pathway activation cooperates with VHL
loss to induce ccRCC [73–75], SLC38A1 probably plays an important role in the progression of ccRCC.
Third, glutamine can contribute to the de novo synthesis of GSH through the generation of NADPH via
glutamate dehydrogenase (GLUD) or malate regulation [76]. Overall, glutamine is of vital importance
to GSH de novo synthesis to modulate the oxidative stress level in ccRCC.
Cysteine, although a nonessential amino acid, plays an important role in protein synthesis by
forming intraprotein disulfide bonds to stabilize proteins. There are multiple cellular pathways and
transporters, which contribute to the availability of cysteine in cells. Aside from the γ-glutamyl cycle,
the trans-sulfuration pathway serves as an important source for cysteine recruitment, which has
been reported to be dysregulated in ccRCC [34,36]. Thereby, methionine is converted to S-adenosyl
methionine (SAM), is hydrolyzed to homocysteine, and can then enter the trans-sulfuration pathway,
where it gets converted into cystathionine, which forms cysteine in subsequent reactions [77].
Metabolome profiling of ccRCC tumors has identified elevated SAM, S-adenosyl homocysteine
(SAH), and homocysteine in ccRCC compared to healthy kidney tissues [34,36], indicating a high
demand for cysteine, which is synthesized through the trans-sulfuration pathway. Cystine, the oxidized
dimer of cysteine, can also be absorbed from the tumor microenvironment by xCT (SLC7A11), which is
a heterodimeric cystine–glutamate antiporter [78], where overexpression is associated with overall
poor survival in ccRCC [26].
3.3. Increased Flux of the Pentose Phosphate Pathway in ccRCC to Support GSH Synthesis
The pentose phosphate pathway (PPP) is, in part, a metabolic pathway parallel to glycolysis.
It generates NADPH and pentoses, including ribose 5-phosphate (R5P). Its primary role is considered
to be anabolic rather than catabolic, as it provides R5P, a precursor for the synthesis of nucleotides.
NADPH is an important cofactor for the enzyme GSH reductase (GR) to catalyze the reduction of
GSSG to GSH and hence links PPP directly to GSH synthesis. Therefore, high GSH/GSSG ratios in
ccRCC can also be explained by increased flux through PPP, which provides the necessary molecules of
NADPH for GSH conversion [26,34,79]. Indeed, glucose-6-phosphate dehydrogenase (G6PD), which
determines the production of NADPH and R5P within PPP, was found to be increased in ccRCC, and its
elevation was associated with higher levels of NADPH and PPP-derived metabolites [79]. Furthermore,
the inhibition of G6PD in chRCC cells decreased the NADPH level and increased ROS production to
significantly impair cancer cell survival, suggesting that PPP plays a fundamental role in the regulation
of redox homeostasis and progression in ccRCC [79]. Recently, fructose 1,6-bisphosphate (FBP), a
glycolytic intermediate, was found to be accumulated in ccRCC, leading to the suppression of NADPH
oxidase 4 (NOX4), which caused an increase in NADPH and a decrease in ROS, independent of
PPP [80]. These changes were caused by the downregulation of aldolase B (ALDOB), which portended
significantly worse survival in ccRCC patients [80].
3.4. Fumarate Hydratase Mutations and GSH in Type II pRCC
Fumarate hydratase (FH) is frequently mutated in type II pRCC, causing FH deficiency and
affecting the normal flux of the TCA cycle [42,43]. The FH deficiency of this tumor leads to metabolic
reprogramming, including impaired oxidative phosphorylation and aerobic glycolysis, known as
the “Warburg effect”, which is probably caused by the stabilization of HIF through fumarate
accumulation [44,45]. A further study showed that the accumulation of fumarate was fueled by
glutamine rather than glucose in type II pRCC cells [81]. Apart from causing HIF stabilization,
fumarate accumulation has been reported to activate NRF2 and its downstream ARE pathway [82,83].
Moreover, somatic mutations of NRF2 and its regulator Kelch-like ECH-associated protein 1 (KEAP1)
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have been reported to be highly correlated with poor prognosis in type II pRCC and pancreatic
cancer [82,84,85]. NRF2 plays an important role in cellular redox balance as a transcription factor
that regulates the expression of various genes to combat the harmful effects of extrinsic and intrinsic
damage, such as xenobiotics and oxidative stress. NRF2 is primarily regulated by KEAP1, a substrate
adapter protein of Cullin 3 (CUL3), which contains an E3 ubiquitin ligase activity. Under normal
conditions, NRF2 builds a complex with KEAP1 via its Kelch domain for ubiquitination, and NRF2 is
then targeted for subsequent proteasomal degradation [84,86,87]. However, in response to a diverse
array of stimuli, such as oxidative stress, the cysteine residues within KEAP1, Cys151, Cys273, and
Cys288 can be modified, which results in a conformational change along with the dissociation of
NRF2 to avoid KEAP1-mediated degradation [84,87]. Stabilized NRF2 can then translocate to the
nucleus and bind to ARE to activate the downstream effector genes of at least two pathways involved
in cytoprotection [84]. First, NRF2 can activate genes involved in regulating GSH synthesis and
metabolism by activating GCL [85], and second, NRF2 promotes the expression of genes coding for
antioxidant proteins, such as GSH peroxidases (GPXes) and GSH S-transferases (GSTs). GPX is an
enzyme family with peroxidase activity that protects cells from oxidative damage, and GSTs are
comprised of a family of isozymes that catalyze the conjugation of GSH to xenobiotic substrates for
detoxification [78,84]. Additionally, fumarate can directly bind to GPX1 through interaction with the
Thr143 and Asp144 residues, and fumarate accumulation is thus able to activate GPX1 and decrease
the ROS level in cells [88].
Apart from mutations in FH, NRF2, CUL3, or KEAP1 in type II pRCC, several other mechanisms
can also lead to increased NRF2 activity in other cancers, including epigenetic silencing, modifications
of cysteine residues, metabolic alterations, and oncogene-dependent signaling [85].
3.5. Glutathione Salvage Pathway in chRCC
One member of the membrane transpeptidase family GGT is γ-glutamyl transferase 1 (GGT1),
which can remove and transfer the γ-glutamyl moiety from extracellular GSH, GSSG, or even GSH
conjugates to an amino acid acceptor, known as the GSH salvage pathway. This degradation of
extracellular GSH species fuels the cytoplasm of cells to maintain intracellular GSH levels [67]. Recent
metabolomic profiling studies have identified significantly increased amounts of GSH, GSSG, and its
precursor γ-glutamyl cysteine in chRCC compared to normal kidney tissue [57,60]. Unlike in ccRCC,
significantly lower expression of GGT1 has been reported in chRCC [57,60]. The specific loss of GGT1 in
chRCC leads to an increased sensitivity to oxidative stress, mitochondrial damage, and reprogramming
of glutamine and glucose metabolism [60]. Interestingly, renal oncocytomas, which are considered
to be the benign counterpart of chRCC, were found to have a similar increase of GSH moieties and
decreased levels of GGT1 relative to normal kidney tissue [61].
4. Therapeutic Strategies to Exploit Increased GSH Levels in RCC
Nonmetastatic primary RCC can be removed by partial or complete nephrectomy. Metastases
that occur in about one-third of all RCC patients must be treated with various therapeutic agents [89].
One severe problem is that the malignancies gain a fast treatment resistance through the activation
of alternative metabolic pathways, or parts of the cancer cells that are not responsive outgrow
the responsive tumor cells. For example, angiopoietin 2, MET, or Interleukin (IL) can serve as
alternative angiogenesis factors, or the AKT/PI3K/mTOR pathway can stimulate proliferation upon its
activation [90,91]. Depletion of GSH alone has been shown to be insufficient to induce cell death in most
cancer cell lines. The imposed selective pressure during cancer initiation and progression led to a robust
adaption mechanism to tolerate these stress conditions [92]. To overcome these limitations, combinatory
therapies targeting two independent mechanisms are promising. The following subchapters highlight
current strategies that manipulate GSH metabolism and intend to eradicate RCC.
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4.1. The Cystine–Glutamate Shuttle Inhibitor
xCT is a cystine–glutamate antiporter that is essential to the uptake of cystine (Figure 1). After the
conversion of cystine into cysteine, it serves as a building block for the synthesis of intracellular GSH,
as discussed before. xCT is upregulated in a variety of cancers, where the antiporter-assisted production
of GSH reduces oxidative stress levels to protect cancer from apoptosis [93]. Pharmacological inhibition
of xCT decreases cystine uptake and induces ferroptosis in cancer cells [94], which makes xCT inhibitors
potential treatment agents for cancer.
Sorafenib, an FDA-approved kinase inhibitor drug used for almost 15 years for the treatment of RCC,
has multiple kinase inhibition activities, including cell surface tyrosine kinases (e.g., vascular endothelial
growth factor receptor, VEGFR; platelet-derived growth factor receptor, PDGFR; tyrosine-protein kinase
kit, KIT; Fms-like tyrosine kinase 3, FLT3; RET proto-oncogene, RET) and downstream intracellular
serine/threonine kinases (e.g., both wild-type and mutant BRAF and CRAF) [95]. As these kinases play
important roles in cancer cell proliferation, angiogenesis, and apoptosis, sorafenib has been shown to
inhibit the proliferation of cancer cells and induce apoptosis in vitro, as well as reduce angiogenesis and
inhibit tumor growth in vivo [95]. Recently, sorafenib, but not other kinase inhibitors of the same class,
has been reported by several studies to have novel inhibition activity versus xCT, leading to decreased
cysteine uptake, GSH depletion, and ROS accumulation, finally causing endoplasmic reticulum stress
and ferroptosis [94,96,97].
Besides sorafenib, there are two other xCT inhibitors worth discussing in more detail, erastin
and sulfasalazine. Erastin is a small molecule that inhibits xCT activity through the mitochondrial
voltage-dependent anion channel 2 and 3 (VDAC2 and VDAC3), causing abolition of the antioxidant
defenses of the cell, and it furthermore has selectively lethal activity toward oncogenic RAS mutant
cell lines [98,99]. A cystine addiction of VHL-deficient RCC cells was identified, and the deprivation
thereof or treatment with erastin or sulfasalazine in RCC cells induced cell death [100]. Chromophobe
RCC, but not pRCC, was found to have significantly increased abundances of the VDAC1, VDAC2,
and VDAC3 proteins [46,57] and should have a good response to treatment with erastin. Sulfasalazine
has been in use for over 50 years for the treatment of inflammatory conditions such as arthritis. It is a
well-characterized specific inhibitor of xCT and shows anticancer effects on multiple types of cancers,
including RCC [94,98,100]. The safety and side effects of sulfasalazine are well investigated and
understood, and this old drug has the potential to be a novel, effective, and economical treatment
option for RCC patients.
4.2. Glutaminase 1 Inhibitor
Glutaminase 1 (GLS1), a key mitochondrial enzyme that controls glutamine metabolism and
contributes to de novo GSH synthesis (Figure 1), is very important for tumor proliferation and survival.
The glutaminase inhibition of glutamine-addicted cancer cells leads to the disruption of metabolic
pathways, such as macromolecule synthesis, ATP production, and the intracellular redox balance [101].
Thus, targeting glutaminase to disrupt vital metabolic pathways of tumors is considered to be a novel
strategy to treat cancer.
CB-839, a potent, selective, and orally bioavailable GLS1 inhibitor, has been reported to exhibit
significant antiproliferative activity in multiple cancer cell lines and has shown an antitumor effect
in tumor xenografts and cancer patients [102]. CB-839 is currently being investigated in multiple
phase 1 and 2 clinical trials for patients with locally advanced, metastatic, and/or refractory solid
tumors, including ccRCC [102]. Emberley et al. [102] reported a cytotoxic effect of CB-839 in 18 out
of 23 tested RCC cell lines and 0 out of 6 non-RCC cell lines. MacKinnon et al. [103] found that the
abundance of pyruvate carboxylase (PC), which catalyzes the conversion of pyruvate to oxaloacetate
to fuel the TCA cycle, strongly correlated with resistance, and knockdown of PC reduced TCA cycle
activity and sensitized cells to CB-839 treatment, suggesting that PC expression may be a biomarker
of resistance to CB-839. Chromophobe RCC and pRCC have been reported recently to have low
PC expression [46,57]: They may lack this mechanism and therefore would probably be sensitive to
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CB-839. In addition, decreases in mTOR signaling were also observed in RCC cell lines that were
sensitive to CB-839, indicating that CB-839-induced glutamate deprivation has a direct influence on
the mTOR pathway [102]. These observations suggest that receptor tyrosine kinase (RTK) signaling
or mTOR inhibitors would have synergistic effects with CB-839 to increase cytotoxicity in RCC cell
lines. The combined CB-839 and cabozantinib (RTK inhibitor) therapy, which reached phase 2 clinical
evaluation (CANTATA: NCT03428217), showed pronounced reductions in TCA cycle activity and in
signaling via AKT and ERK compared to single-agent treatments. When applying CB-839 in combination
with everolimus (mTOR inhibitor) to RCC cell lines in vitro and to a Caki-1 RCC xenograft model
in vivo, synergistic antitumor activity and inhibition of both glucose and glutamine utilization were
observed [104]. Furthermore, the combined therapy of CB-839 with everolimus in a phase 1 clinical
trial showed a 100% disease control rate (DCR) in ccRCC and 67% in pRCC [104], and it is currently
in a phase 2 investigation in patients with advanced ccRCC (ENTRATA: NCT03163667). Moreover, a
phase 1/2 study of CB-839 in combination with nivolumab (anti-PD-1 antibody) is currently ongoing
(NCT02771626) and has shown a 74% DCR in ccRCC patients. Furthermore, CB-839 was found to
have a synergistic effect in selectively suppressing the growth of ccRCC cells in vitro and in vivo when
combined with poly(ADP-ribose) polymerase (PARP) inhibitors [105]. Currently, a phase 1b/2 clinical
trial of CB-839 in combination with talazoparib (PARP inhibitor) is under investigation (NCT03875313).
At present, CB-839 is the only small-molecule GLS1 inhibitor being studied in a clinical setting,
but there are other GLS1 inhibitors in preclinical investigations, including bis-2-(5-phenylacetamido-
1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), 6-diazo-5-oxo-l-norleucine (DON), and 5-[3-bromo-4-
(dimethylamino)phenyl]-2,3,5,6-tetrahydro-2,2-dimethyl-benzo[a]phenanth-ridin-4(1H)-one (968).
Two of these GLS1 inhibitors have not been further applied and investigated in clinical studies
due to the low solubility and potency of BPTES and the high toxicity and poor binding selectivity of
DON [106]. However, 968 is known to be a noncompetitive inhibitor of GLS1 and is currently still in
the preclinical stage [106].
4.3. The Glutamate–Cysteine Ligase Inhibitor Buthionine Sulfoximine
GCL, the enzyme catalyzing the first reaction in GSH de novo synthesis (Figure 1), plays an
important function in maintaining intracellular GSH levels to combat oxidative stress in RCC [65,66].
Thus, targeting GCL for the treatment of RCC remains a potentially effective strategy to benefit patients.
Buthionine sulfoximine (BSO) is a specific and competitive inhibitor of GCL [107]. Developed in
1979 by Griffith and Meister [108], BSO is able to decrease the intracellular GSH level and sensitize
different types of cancers both in vitro and in vivo to various chemotherapies and other cytotoxic
therapies, e.g., irradiation and hyperthermia [107,109]. BSO has been reported to enhance the activity
of melphalan, doxorubicin, daunorubicin, and other cytotoxic agents in myeloma, breast cancer, and
lung cancer [107,109]. Two clinical trials of BSO in combination with melphalan were conducted for
the treatment of neuroblastoma. In a pilot study and a phase I clinical trial, BSO in combination with
melphalan was well tolerated and had therapeutic activity toward recurrent and refractory high-risk
neuroblastoma (NCT00002730, NCT00005835) [110,111]. Sorafenib, as discussed earlier, has xCT and
multiple kinase inhibition activity. However, it has been reported that some RCC patients were initially
resistant or acquired resistance to sorafenib within a median of 5–9 months [112]. Mechanistic studies
have shown that the resistance to sorafenib in RCC was mediated by enhanced expression of HIF
and numerous HIF-regulated genes, such as VEGF [112,113]. As the redox state could regulate HIF
expression and downstream substrates to cause drug resistance [29,114], BSO, which can regulate the
redox environment through GSH, was shown to be able to decrease the expression of HIF [114–116].
These studies indicate that combination therapies with BSO and sorafenib might overcome the drug
resistance of sorafenib in resistant RCC patients.
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4.4. Inhibition of Deubiquitinating Enzymes Initiates Proteotoxicity
A recent report outlined a combinatory treatment strategy applying the before-mentioned GCL
inhibitor BSO together with deubiquitinating enzyme (DUB) inhibitors [92]. Individual DUB inhibitors,
such as MI-2, PR-619, and EERI, were not effective in inducing cell death alone but led to an
induction of proteotoxic stress and cell death in combination with BSO in many different cancer
cell lines. Though the exact molecular role of how DUBs can protect cells from oxidative stress
is still elusive, a dependency on DUB activity to maintain protein homeostasis by eliminating the
accumulation of damaged and potentially cytotoxic polyubiquitinated proteins and cell viability have
been proposed [92]. This hypothesis was supported by a study profiling the ubiquitination status
between ρ0 cells, which entirely lack mitochondrial DNA, and their parent cell line 143B.TK¯. The
significant decrease in the global ubiquitination pattern in ρ0 cells can be explained by the lack of main
ROS generators localized within the oxidative phosphorylation system, namely complex I and III,
which reduce the oxidative damage of proteins to a minimal level [47].
This combination of DUB and GSH inhibitors has not been applied to RCC cell lines yet but would
present a valuable new strategy to trigger proteotoxic stress as a potential beneficial treatment in RCC
cell lines and animal models.
4.5. The Role of GSH Metabolism in the Immune Microenvironment of the Tumor
Traditional immunotherapies using interleukin-2 or interferon-alfa on metastatic RCC have presented
limited efficacy and highly toxic side effects [117,118]. In recent years, a new generation of immunotherapy
utilizing a novel strategy to block immune checkpoints has shown promising efficacy and manageable
toxicity and has emerged as a new milestone for RCC treatment [119]. Currently, the approved
immune checkpoint inhibitors for RCC are ipilimumab (a cytotoxic T lymphocyte-associated protein 4
[CTLA-4] inhibitor) [120], the programmed cell death 1 (PD-1)-specific antibodies nivolumab [121] and
pembrolizumab, and the programmed death-ligand 1 (PD-L1) antibody avelumab.
A main metabolic feature of RCC is the reprogramming of the main metabolic pathways, which
helps cancer cells adapt to and simultaneously shape the tumor microenvironment. Immune cells utilize
different metabolic programs for their differentiation and effective functions. These immune–metabolic
pathways can be modified or “highjacked” in the tumor microenvironment and thus affect the normal
functions of immune cells, e.g., by infiltrating tumor tissues and presenting tumor-associated antigens
to T-cells [122]. Therefore, a huge effort has been put into the development of immunotherapies to take
advantage of the complex crosstalk between immune cells and the tumor [123].
How does GSH metabolism influence this crosstalk in RCC? Though there is sparse literature
on this topic, it has been shown that GSH metabolism can influence the immune microenvironment
in cancer at least in the following two aspects. First, glutamine is a crucial nutrient for the effector
function of T-cells. Glutamine deprivation or its transporter deficiency blocks the differentiation of
T-helper 1 and 17 cells [124,125]. Similarly, the proliferation and differentiation of B-cells also requires
glutamine [126]. As glutamine addiction is one of the main features of RCC, glutamine may be a
limiting nutrient factor in the tumor microenvironment, and thus a lack of glutamine can induce
immunosuppression. Second, T-cell stimulation activates the cystine–glutamate antiporter xCT and
leads to increased uptake of cystine and subsequent GSH synthesis [122]. Reduced GSH levels in
antigen-presenting cells have been shown to influence antigen processing and presentation as well as
T-cell differentiation into T-helper 1 or 2 phenotypes [127]. Furthermore, GSH can bind to anticancer
drugs, and these conjugates can be eﬄuxed out of the cell via multiple resistance-associated protein
transporters, which are the underlying reasons for therapeutic resistance in some cancers [128]. All the
points discussed above impressively show how tumor cells compete with immune cells for GSH-related
nutrients in the tumor microenvironment, but more research on the immune response in RCC is needed
to exploit these mechanisms for new therapy development.
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5. Conclusions
Altered GSH metabolism contributes significantly to the development and progression of all renal
malignancies but could, at the same time, be the key to potential therapies. All RCCs have a reduced
oxidative phosphorylation capacity in common. The dysregulated respiratory chain is the main source
of electron leakage, resulting in excessive ROS. Raised oxidative stress levels in RCC are counteracted
by tremendously increased GSH levels and thereby potentially prevent immune reactions, apoptosis,
or other forms of cell death as a strategy to foster the survival of the malignancy. Many applied
chemotherapeutics initiate an additional production of ROS as one potent mechanism to eradicate
RCC, frequently accompanied by the supplementation of antioxidants in the past. Not surprisingly,
targeting ROS by antioxidants and the simultaneous generation of ROS by chemotherapeutics has
led to mixed results in the treatability of RCC [14]. New therapeutic ways exploit sensitivity toward
inhibitors of the GSH metabolism, such as xCT, glutaminase, and GCL. However, the inhibition of just
one altered pathway to cure RCC turned out to be not successful either, as cells are fitted by a very
flexible system to compensate for the impairment of one pathway or mechanism. New studies have
shown that a combinatory therapy targeting two independent pathways and one involved in ROS
metabolism is key to improving the survival rate and eventually curing RCC. Although the main role
of GSH and other antioxidants is to scavenge intracellular ROS to maintain an overall healthy pro-
and antioxidant exposure status in cells, GSH can also function as a signaling molecule or as a donor
of the post-translational modification S-glutathionylation to regulate protein bioactivity, which was
not discussed in this review. These diverse functions of GSH, a molecule that was identified more
than 100 years ago, still need to be further investigated for better understanding of the underlying
disease mechanisms in cancer. This might facilitate the development of GSH-related modulators with
improved therapeutic efficiencies in the future.
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ccRCC Clear cell renal cell carcinoma
CDKN2A Cyclin-dependent kinase inhibitor 2A
CDKN2B Cyclin-dependent kinase inhibitor 2B
chRCC Chromophobe renal cell carcinoma
CRAF Proto-oncogene C-RAF
CTLA-4 Cytotoxic T lymphocyte-associated protein 4
CUL3 Cullin 3
DCR Disease control rate
DON 6-diazo-5-oxo-l-norleucine
DUB Deubiquitinating enzyme
EGFR Epidermal growth factor receptor
EGLN Egl-nine homolog
FAK Focal adhesion kinase
FBP Fructose 1,6-bisphosphate
FBP1 Fructose 1,6-bisphosphatase 1
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FH Fumarate hydratase
FLT3 Fms-like tyrosine kinase 3
G6PD Glucose-6-phosphate dehydrogenase
GCL Glutamate cysteine ligase
GCLC Glutamate cysteine ligase catalytic subunit
GCLM Glutamate cysteine ligase modulatory subunit
GGT γ-glutamyl transferase




GLUT1 Glucose transporter type 1
GPX Glutathione peroxidase
GR Glutathione reductase
GSH Glutathione reduced form
GSS Glutathione synthetase
GSSG Glutathione oxidized form
GST Glutathione S-transferase
HGF Hepatocyte growth factor
HIF Hypoxia inducible factor
KEAP1 Kelch-like ECH-associated protein 1
KIT Tyrosine-protein kinase kit
MET Proto-oncogene c-Met
MYC MYC proto-oncogene
NADPH Nicotinamide adenine dinucleotide phosphate
NOX4 NADPH oxidase 4
NRAS NRAS proto-oncogene, GTPase
NRF2 Nuclear factor erythroid 2-related factor 2
ODD Oxygen-dependent degradation
PC Pyruvate carboxylase
PD-1 Programmed cell death 1
PD-L1 Programmed cell death-ligand 1
PDGFR Platelet-derived growth factor receptor
PPP Pentose phosphate pathway
pRCC Papillary renal cell carcinoma
R5P Ribose 5-phosphate
RCC Renal cell carcinoma
RET RET proto-oncogene
ROS Reactive oxygen species
RTK Receptor tyrosine kinase
SAH S-adenosyl homocysteine
SAM S-adenosyl methionine
SETD2 Set domain-containing 2, histone lysine methyltransferase
SLC38A1 Solute carrier family 38 member 1
SLC7A11 Solute carrier family 7 member 11
TERT Telomerase reverse transcriptase
TFE3 Transcription factor E3
TSC1 Tuberous sclerosis 1 protein
TSC2 Tuberous sclerosis 2 protein
VDAC1 Voltage-dependent anion channel 1
VDAC2 Voltage-dependent anion channel 2
VDAC3 Voltage-dependent anion channel 3
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
VHL von Hippel-Lindau
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